Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.69 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the importance of ongoing clinical trials. They did not provide specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing clinical trials and product development.
Madrigal Pharmaceuticals reported a loss of $0.69 per share for Q2 2017, with no revenue figures disclosed. The stock reacted negatively, dropping 0.70%, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to navigate its clinical trials without clear financial expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CREDICORP LTD
Aug 7, 2017